It’s one down and two to go both for Bristol-Myers Squibb Co. and for shareholders in the former Celgene Corp. as ozanimod obtained US Food and Drug Administration approval for relapsing multiple sclerosis on 26 March, about two years after the FDA issued a “refuse-to-file” letter for the drug citing insufficient clinical and non-clinical pharmacology data in the new drug application.
BMS Gets US Approval Of Ozanimod For Relapsing MS, But Launch Delayed
Zeposia, one of three Celgene candidates central to last year’s merger with BMS, obtains US FDA approval in relapsing MS. BMS, however, will delay the launch due to the COVID-19 pandemic.
